EORTC CEO, APPOINTED CO-CHAIR OF ACT EU ADVISORY GROUP
We are pleased to announce that Dr Denis Lacombe, EORTC CEO, has been appointed as the stakeholder co-chair of the Accelerating Clinical Trials in the EU (ACT EU) advisory group for a two-year mandate.
This role offers new opportunities to collaborate more closely with regulatory bodies and other stakeholders, addressing daily challenges and developing new opportunities for conducting clinical research in Europe.
Additionally, Stephanie Kromar, Head of the Regulatory Department, and Stephane Lejeune, Head of the International Affairs and Policies Department, will represent EORTC on the ACT EU Advisory Group.
ACT EU is a unique initiative aimed at optimising the conduct of clinical research in Europe by addressing challenges arising from the rapidly evolving regulatory ecosystem and developing a specific scheme for academic clinical research. The European Commission, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) run the ACT EU initiative together.
You can also help support EORTC’s game-changing clinical research to unleash scientific breakthrough and transform cancer patients’ lives. Learn how to GET INVOLVED, or Make a Contribution Now.
Leave A Comment